Everything drug pricing and policy, every day
And new work from NPC suggests that the IRA disincentives in orphan drugs are -- unfortunately -- impacting development
And introducing a new Apex resource: the List- and Net-Price Disclosures spreadsheet
And when it comes to drug pricing, can you tell a Trump quote from a Bernie quip?
And a look at where an estimate for the costs of a pill penalty fix goes wrong
And the hidden PBM and IRA reforms buried in early drafts of reconciliation legislation
And Monday is apparently the day for the big MFN order
And what Hims’ earnings call says about the future of pharma
And the next 15 drugs in the IRA crosshairs, according to Cantor analysts
Plus thinking on the revelations and limitations of list- and net-price disclosures
